Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 12:8:814497.
doi: 10.3389/fmed.2021.814497. eCollection 2021.

New Aspects of Kidney Fibrosis-From Mechanisms of Injury to Modulation of Disease

Marcus J Moeller  1   2 , Rafael Kramann  1   3   4 , Twan Lammers  5 , Bernd Hoppe  6   7 , Eicke Latz  8 , Isis Ludwig-Portugall  9 , Peter Boor  1   10 , Jürgen Floege  1 , Christian Kurts  9   11 , Ralf Weiskirchen  12 , Tammo Ostendorf  1
Affiliations
Review

New Aspects of Kidney Fibrosis-From Mechanisms of Injury to Modulation of Disease

Marcus J Moeller et al. Front Med (Lausanne). .

Abstract

Organ fibrogenesis is characterized by a common pathophysiological final pathway independent of the underlying progressive disease of the respective organ. This makes it particularly suitable as a therapeutic target. The Transregional Collaborative Research Center "Organ Fibrosis: From Mechanisms of Injury to Modulation of Disease" (referred to as SFB/TRR57) was hosted from 2009 to 2021 by the Medical Faculties of RWTH Aachen University and the University of Bonn. This consortium had the ultimate goal of discovering new common but also different fibrosis pathways in the liver and kidneys. It finally successfully identified new mechanisms and established novel therapeutic approaches to interfere with hepatic and renal fibrosis. This review covers the consortium's key kidney-related findings, where three overarching questions were addressed: (i) What are new relevant mechanisms and signaling pathways triggering renal fibrosis? (ii) What are new immunological mechanisms, cells and molecules that contribute to renal fibrosis?, and finally (iii) How can renal fibrosis be modulated?

Keywords: crystals; deep learning; fibrosis imaging; inflammasome; lupus erythematodes; myofibroblast; parietal epithelial cell; renal fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The main cellular source of kidney myofibroblasts following kidney injury and fibrosis progression are resident renal fibroblasts and pericytes.
Figure 2
Figure 2
Identification of different kidney myofibroblast subtypes in renal fibrosis. In kidney fibrosis two different types of myofibroblasts could be discriminated: PDGFRβ+/CD45− myofibroblasts and PDGFRβ+/CD45+ myofibroblasts-like cells. PDGFRβ+/CD45− fibroblasts originate from pericytes and fibroblasts but not from proximal tubule epithelium and secrete extracellular matrix proteins. Circulating cells of the hematopoietic lineage differentiate in PDGFRβ+/CD45+ myofibroblasts-like cells. These myofibroblasts-like cells secrete extracellular matrix, pro-inflammatory, profibrotic chemokines and interact via receptor-ligand-binding with PDGFRβ+/CD45− myofibroblasts.
Figure 3
Figure 3
Simplified scheme to illustrate renal inflammasome activation by two disease entities, finally leading to renal fibrosis. SLE, systemic lupus erythematosus; MDSCs, myeloid-derived suppressor cells. Modified based on (25).
Figure 4
Figure 4
Three known gene defects in hepatocytes cause oxalate accumulation in primary Hyperoxaluria I-III. Ca-Oxalate crystals precipitate in the kidney where water gets reabsorbed and the solubility coefficient of this salt is exceeded. The crystals activate the inflammasome in renal macrophages and dendritic cells, which stimulate interstitial fibroblasts to deposits collagen, resulting in kidney fibrosis.
Figure 5
Figure 5
The figure summarizes some central aspects of the repair and modulation of renal fibrosis that have been successfully investigated in our consortium. PODs, podocytes; fPECs, flat parietal cells; PTLC, proximal tubular epithelial-like cell, PDGFs, platelet-derived growth factors; MIF, macrophage migration inhibitory factor.
Figure 6
Figure 6
Pathogenesis of sclerotic lesions in FSGS. (A) Normal glomerulus. gray, podocytes; white, parietal epithelial cells. (B) Podocyte injury or loss triggers focal PEC activation (red), PECs form an adhesion to the capillary tuft (arrow). (C) PECs take over parts of the capillary segment, capillaries are lost. (D) Advanced stage. Figure taken from (56) with modifications.
Figure 7
Figure 7
Imaging kidney fibrosis. (A) 2D and 3D images reconstructed from contrast-enhanced micro-CT imaging show progressive vessel rarefaction in mice with I/R-induced kidney fibrosis. Scale bar: 200 μm. (B) Molecular imaging of collagen deposition in the kidneys of mice with I/R-induced fibrosis, employing CNA35 and CT-FMT. (C) Validation of CNA35 binding to perivascular collagen fibers in mice with I/R-induced kidney fibrosis. Perfused blood vessels are stained with lectin. (D) ESMA-enhanced molecular MR imaging of elastin deposition in the kidneys of mice with adenine diet-induced fibrosis. (E–G) In the adenine reversal model (14 days on adenine diet, then 14 days recovery), ESMA-based molecular MRI can detect residual fibrosis that is not detected by routine kidney function assessment, i.e. analysis of creatinine clearance. Scale bar in (E): 50 μm. Images reproduced, with permission, from (–59). For assessing statistical significance, as shown in (F) and (G), one-way analysis of variance (ANOVA) followed by Bonferroni correction was used. Statistical significance was defined as *p < 0.05; **p < 0.01; ***p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. . Prevalence of chronic kidney disease in the United States. JAMA. (2007) 298:2038–47. 10.1001/jama.298.17.2038 - DOI - PubMed
    1. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. (2010) 6:643–56. 10.1038/nrneph.2010.120 - DOI - PubMed
    1. Rockey DC, Bell PD, Hill JA. Fibrosis - a common pathway to organ injury and failure. N Engl J Med. (2015) 372:1138–49. 10.1056/NEJMra1300575 - DOI - PubMed
    1. Schunk SJ, Floege J, Fliser D, Speer T. WNT-β-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. (2021) 17:172–84. 10.1038/s41581-020-00343-w - DOI - PubMed
    1. Jung HJ, Kim H-J, Park K-K. Potential roles of long noncoding RNAs as therapeutic targets in renal fibrosis. Int J Mol Sci. (2020) 21:2698. 10.3390/ijms21082698 - DOI - PMC - PubMed

LinkOut - more resources